Irisin Protects Against Diabetic Cardiomyopathy by Suppressing Ferroptosis
Drug Development Research · 2025
DOI: 10.1002/ddr.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Hongmei Ye und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Peking University People's Hospital, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Ferroptosis, Fibronectins, Diabetic Cardiomyopathies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: This study was supported by the National Natural Science Foundation of China (Grant no. 82104156), Peking University People's Hospital Scientific Research Deve…, National Natural Science Foundation of China.
Abstract (Originalsprache)
Diabetic cardiomyopathy (DCM) is a major cause of mortality in patients with diabetes, particularly those with type 2 diabetes. Ferroptosis is closely linked to the onset and progression of various cardiovascular diseases. Irisin, a myokine produced by exercising skeletal muscle, has been shown to mitigate DCM. However, whether irisin alleviates type 2 DCM by inhibiting ferroptosis remains unclear. This study aimed to determine whether irisin prevents DCM by suppressing ferroptosis. First, ferroptosis was examined in palmitic acid (PA)‐induced cardiomyocytes. Next, the effects of irisin on PA‐induced cardiomyocytes were evaluated. Finally, the molecular mechanisms underlying irisin's protective effects against DCM were investigated. Ferroptosis was identified in an In Vitro model of type 2 DCM induced by PA. Irisin reduced PA‐induced ferroptosis and alleviated myocardial injury, as indicated by decreased reactive oxygen species (ROS) production, Fe²⁺ content, and malondialdehyde (MDA) levels, along with increased glutathione (GSH) levels and mitochondrial membrane potential (MMP). Further analysis suggested that irisin does not mitigate PA‐induced ferroptosis through iron metabolism or lipid peroxidation pathways but instead inhibits ferroptosis via the System Xc‐/GSH/GPX4 axis. Additionally, irisin reduced the secretion of inflammatory cytokines, including IL‐1β and IL‐6. These findings indicate that irisin prevents the progression of DCM by suppressing ferroptosis through the System Xc‐/GSH/GPX4 axis and reducing inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Peking University People's Hospital, Beijing, People's Republic of China.
- Clinical Trial Site of Peking University People's Hospital, Beijing, People's Republic of China.
- School of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
ORCID-Profile: Jing Guo
Förderung
- This study was supported by the National Natural Science Foundation of China (Grant no. 82104156), Peking University People's Hospital Scientific Research Deve…
- National Natural Science Foundation of China
Zitieren
APA
Ye, H., Guo, J., Wang, X., Chen, B., Hu, L., Liu, B., Song, R., Feng, Y., & Zhang, X. (2025). Irisin Protects Against Diabetic Cardiomyopathy by Suppressing Ferroptosis. Drug Development Research. https://doi.org/10.1002/ddr.70077
Vancouver
Ye H, Guo J, Wang X, Chen B, Hu L, Liu B, et al. Irisin Protects Against Diabetic Cardiomyopathy by Suppressing Ferroptosis. Drug Development Research. 2025. doi:10.1002/ddr.70077
BibTeX
@article{Ye2025,
author = {Ye, Hongmei and Guo, Jing and Wang, Xinyu and Chen, Bixian and Hu, Lei and Liu, Boyu and Song, Rongjing and Feng, Yufei and Zhang, Xiaohong},
title = {Irisin Protects Against Diabetic Cardiomyopathy by Suppressing Ferroptosis},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70077}
}
EUVIMED